Henatinib (maleate)
Henatinib maleate is an orally active small-molecule multikinase inhibitor that has demonstrated broad and potent antitumor activities. Henatinib maleate inhibits the activity of VEGFR-2, c-kit, PDGFR with IC50 values of 0.6 nM, 3.3 nM and 41.5 nM, respectively. Henatinib maleate significantly inhibits VEGFR-2 phosphorylation and its downstream signal pathway[1][2].
Product Specifications
CAS Number
1239269-52-3
UNSPSC
12352005
Target
C-Kit; PDGFR; VEGFR
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
OC(/C=C\C(O)=O)=O.O=C(/C(C1=C2)=C\C3=C(C4=C(CCCN(C4=O)C[C@H](O)CN5CCOCC5)N3)C)NC1=CC=C2F
Molecular Formula
C29H33FN4O8
Molecular Weight
584.59
References & Citations
[1]Jun Qian, et al. Determination of henatinib in human plasma and urine by liquid chromatography-tandem mass spectrometry and its pharmacokinetic application. J Pharm Biomed Anal. 2013 Jun;80:173-9. |[2]Haitian Quan, et al. Abstract 4259: Preclinical anti-tumor study of henatinib, a novel and selective inhibitor of VEGFR-2 in phase I clinical trials. Cancer Res (2011) 71 (8_Supplement) : 4259.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC472216-500 1x 500 µL
CD50 / ICAM3 (CG106), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740304-100 1x 100 µL
CD106 / VCAM1 (B-K9), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC881073-100 1x 100 µL
HLA-Aw32 & HLA-A25 (MHC I) (CATA-1), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680204-100 1x 100 µL
Complement C4d (C4D204), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC881879-100 1x 100 µL
Bcl-2 (Apoptosis & Follicular Lymphoma Marker) (rBCL2/796), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details